Literature DB >> 12477847

Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production.

Dawn E Bowles1, Joseph E Rabinowitz, R Jude Samulski.   

Abstract

Marker rescue, the restoration of gene function by replacement of a defective gene with a normal one by recombination, has been utilized to produce novel adeno-associated virus (AAV) vectors. AAV serotype 2 (AAV2) clones containing wild-type terminal repeats, an intact rep gene, and a mutated cap gene, served as the template for marker rescue. When transfected alone in 293 cells, these AAV2 mutant plasmids produced noninfectious AAV virions that could not bind heparin sulfate after infection with adenovirus dl309 helper virus. However, the mutation in the cap gene was corrected after cotransfection with AAV serotype 3 (AAV3) capsid DNA fragments, resulting in the production of AAV2/AAV3 chimeric viruses. The cap genes from several independent marker rescue experiments were PCR amplified, cloned, and then sequenced. Sequencing results confirmed not only that homologous recombination occurred but, more importantly, that a mixed population of AAV chimeras carrying 16 to 2,200 bp throughout different regions of the type 3 cap gene were generated in a single marker rescue experiment. A 100% correlation was observed between infectivity and the ability of the chimeric virus to bind heparin sulfate. In addition, many of the AAV2/AAV3 chimeras examined exhibited differences at both the nucleotide and amino acid levels, suggesting that these chimeras may also exhibit unique infectious properties. Furthermore, AAV helper plasmids containing these chimeric cap genes were able to function in the triple transfection method to generate recombinant AAV. Together, the results suggest that DNA from other AAV serotypes can rescue AAV capsid mutants and that marker rescue may be a powerful, yet simple, technique to map, as well as develop, chimeric AAV capsids that display different serotype-specific properties.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477847      PMCID: PMC140636          DOI: 10.1128/jvi.77.1.423-432.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles.

Authors:  J A Chiorini; L Yang; Y Liu; B Safer; R M Kotin
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

2.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector.

Authors:  T J McCown; X Xiao; J Li; G R Breese; R J Samulski
Journal:  Brain Res       Date:  1996-03-25       Impact factor: 3.252

3.  Role for highly regulated rep gene expression in adeno-associated virus vector production.

Authors:  J Li; R J Samulski; X Xiao
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

5.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

6.  Expression of Aleutian mink disease parvovirus capsid proteins in defined segments: localization of immunoreactive sites and neutralizing epitopes to specific regions.

Authors:  M E Bloom; D A Martin; K L Oie; M E Huhtanen; F Costello; J B Wolfinbarger; S F Hayes; M Agbandje-McKenna
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.

Authors:  E A Rutledge; C L Halbert; D W Russell
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  Genetic assay for small fragments of bacteriophage phi X174 deoxyribonucleic acid.

Authors:  C A Hutchison; M H Edgell
Journal:  J Virol       Date:  1971-08       Impact factor: 5.103

10.  Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1979-07       Impact factor: 41.582

View more
  26 in total

1.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

2.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 3.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 4.  Extracting structural and functional features of widely distributed biological circuits with single cell resolution via tissue clearing and delivery vectors.

Authors:  Jennifer Brooke Treweek; Viviana Gradinaru
Journal:  Curr Opin Biotechnol       Date:  2016-07-06       Impact factor: 9.740

5.  Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization.

Authors:  Michael A Lochrie; Gwen P Tatsuno; Brian Christie; Jennifer Wellman McDonnell; Shangzhen Zhou; Richard Surosky; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 6.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

Review 7.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

Review 8.  Molecular engineering of viral gene delivery vehicles.

Authors:  David V Schaffer; James T Koerber; Kwang-il Lim
Journal:  Annu Rev Biomed Eng       Date:  2008       Impact factor: 9.590

Review 9.  Engineering adeno-associated viruses for clinical gene therapy.

Authors:  Melissa A Kotterman; David V Schaffer
Journal:  Nat Rev Genet       Date:  2014-05-20       Impact factor: 53.242

10.  Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium.

Authors:  Wuping Li; Liqun Zhang; Jarrod S Johnson; Wu Zhijian; Joshua C Grieger; Xiao Ping-Jie; Lauren M Drouin; Mavis Agbandje-McKenna; Raymond J Pickles; R Jude Samulski
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.